Galapagos traded at 43.99 this Wednesday September 28th, decreasing 0.50 or 1.12 percent since the previous trading session. Looking back, over the last four weeks, Galapagos lost 11.47 percent. Over the last 12 months, its price fell by 1.94 percent. Looking ahead, we forecast Galapagos to be priced at 43.27 by the end of this quarter and at 39.52 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
43.99
Daily Change
-1.12%
Yearly
-1.94%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
argenx SE 366.70 -2.60 -0.70% 43.97%
AstraZeneca 10,076.00 153.00 1.54% 14.07%
Biogen 272.67 74.88 37.86% -4.52%
Genmab 2,491.00 14.00 0.57% -8.59%
Gilead Sciences 64.09 1.46 2.33% -9.66%
GRIFOLS 9.08 -0.51 -5.28% -58.19%
GlaxoSmithKline 1,341.60 25.00 1.90% -4.51%
Hikma Pharmaceutical 1,390.50 149.50 12.05% -43.18%
Incyte Corp 67.43 0.99 1.49% -1.81%
Merck 162.55 3.80 2.39% -12.25%
Neurocrine Biosciences 102.22 0.86 0.85% 8.30%
Novartis 74.82 0.43 0.58% -3.12%
Roche Holding 325.45 12.85 4.11% -3.73%
Sanofi 78.71 1.26 1.63% -5.97%
UCB 70.14 0.10 0.14% -25.82%
Vertex Pharmaceuticals 292.02 7.28 2.56% 60.26%

Indexes Price Day Year
NL25 644 -1.63 -0.25% -17.05%
BE20 3388 -3.28 -0.10% -17.89%
EU100 1119 -0.50 -0.04% -12.70%

Galapagos
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.